FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washingt

on, D.C. 20549	0145 45550141
	│ OMB APPROVAL

-	OMB/II I IOVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Lebwohl David					2. Issuer Name <b>and</b> Ticker or Trading Symbol  Intellia Therapeutics, Inc. [ NTLA ]								(Ched	ationship of Reportin k all applicable) Director Officer (give title		g Person(s) to Issuer 10% Own Other (spe		ner
	ELLIA TH	ERAPEUTICS,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/01/2022							X	below)  EVP, Chief Medi		Medic	below)	Jedny	
40 ERIE STREET; SUITE 130  (Street)  CAMBRIDGE MA 02139  (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year) 03/03/2022							6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Ta	able I - Non-D	erivat	ive S	ecurities	s Ac	quired,	Dis	posed o	f, or Be	neficia	ally	Owned				
1. Title of Security (Instr. 3)  2. TransDate (Month/It			е		2A. Deemed Execution Date, if any (Month/Day/Year		, Transaction Disposed Code (Instr.		ties Acquiro I Of (D) (Ins		and 5) Securities Beneficial Owned Fo		Fori ly (D)	Form: (D) or	m: Direct I or Indirect E nstr. 4) (	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	nount (A) or (D)		e	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivativ Security (Instr. 3 and 4)			Derivative ve Security	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amour Numbe Shares	er of		(Instr. 4)			
Stock Option (right to buy)	\$79.85	03/01/2022		A		20,203 <sup>(1)</sup>		(2)		02/28/2032	Common Stock	20,20	3(1)	\$0.00	20,203	3 <sup>(1)</sup>	D	

## **Explanation of Responses:**

- 1. The original Form 4 incorrectly reported the number of options granted as 13,816.
- 2. This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

## Remarks:

/s/ James Basta, attorney-in-fact 03/04/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.